Xuezhikang improves the outcomes of cardiopulmonary resuscitation in rats by suppressing the inflammation response through TLR4/NF-κB pathway

Nrf2 Regulates Microglia-Mediated Phagocytosis and Neuroinflammation after Intracerebral Hemorrhage

“…Monascin is a novel type of Nrf2 agonist [32], and an agonist of peroxidase of PPAR-ɤ, which suppresses oxidative stress in pathological conditions, promotes the absorption of hematoma and reduces intracerebral edema in our animal models of ICH [16,17]. Xuezhikang is an extract of monascin as its primary component; it is primarily used as traditional Chinese medicine to fight atherosclerosis and exert anti-inflammatory effects by inhibiting toll-like receptor 4(TLR4)/ NF-κB [33,34].…”

Comparing the effectiveness of Chinese patent medicines containing red yeast rice on hyperlipidaemia: A network meta‐analysis of randomized controlled trials

“… 81 Xuezhikang is made by high‐tech biotechnology, containing Lovastatin, a statin homolog, a variety of essential amino acids, unsaturated fatty acids, sterols and small amounts of flavonoids. 82 , 83 The main bioactive components of Zhibituo are Lovastatin and Lovastatin acid. 84 The content of Lovastatin in Zhibituo and Xuezhikang was shown to be 2.7 and 11.1 g/kg, respectively.…”

Dexmedetomidine post-conditioning attenuates cerebral ischemia following asphyxia cardiac arrest through down-regulation of apoptosis and neuroinflammation in rats

“…Consequently, microglia will be over-activated after I/R injury and release excess pro-inflammatory cytokines, impairing neural function [ 22 , 23 ]. A growing body of evidence suggests that inflammation is crucial for the pathogenesis of neurological deficits after CA/CPR [ 24 – 27 ]. In this study, we found that the serum levels of TNF-α andIL-1βwere significantly increased after ROSC in the CPR group.…”